Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics

Core Insights - Eli Lilly reported $11.3 billion in revenue for Q2 2024, a 36% year-over-year increase, with an EPS of $3.92 compared to $2.11 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $9.83 billion by 14.99%, and the EPS surpassed the consensus estimate of $2.64 by 48.48% [1] Revenue Performance - Net Sales for Cyramza (Ramucirumab) in the US were $116.10 million, slightly below the average estimate of $119.78 million, marking a 1% year-over-year increase [3] - International Net Sales for Humalog were $196.90 million, slightly below the estimate of $198.53 million, reflecting a 6.5% year-over-year decline [4] - International Net Sales for Forteo were $38.50 million, below the estimate of $42.90 million, showing a significant 23.9% year-over-year decline [5] - International Net Sales for Alimta were $21.40 million, compared to the estimated $28.12 million, representing a 50.4% year-over-year decline [6] - Total Net Sales for Cyramza were $248.90 million, slightly below the estimate of $252.22 million, indicating a 4.4% year-over-year decline [7] - Net Sales for Humulin were $223.60 million, exceeding the estimate of $184.50 million, with an 8.9% year-over-year increase [8] - Net Sales for Humalog reached $631.60 million, significantly above the estimate of $383.68 million, reflecting a 43.4% year-over-year increase [9] - Net Sales for Forteo were $69.90 million, below the estimate of $107.27 million, showing a 52.8% year-over-year decline [11] - Net Sales for Erbitux were $155.80 million, slightly below the estimate of $162.77 million, indicating a 4.1% year-over-year decline [12] - Net Sales for Alimta were $33.90 million, compared to the estimate of $37.38 million, representing a 44.3% year-over-year decline [13] - Net Sales in Oncology reached $2.16 billion, exceeding the estimate of $2.04 billion, with a 29.2% year-over-year increase [14] - Net Sales in Neurosciences were $339.50 million, above the estimate of $287.50 million, reflecting a 12.3% year-over-year decline [15] Stock Performance - Shares of Eli Lilly have returned -17.8% over the past month, compared to the Zacks S&P 500 composite's -6.5% change [15] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [15]